Instrument Inactif

Communiqués Allarity Therapeutics, Inc. Nasdaq Stockholm

Actions

ALLR

US0167441049

Recherche biotechnologique et médicale

Communiqués

07/07	Allarity Therapeutics Announces CLIA Certification, Clearing the Path for Advancing DRP® Testing for FDA Registration	AQ
30/06	Allarity Therapeutics Announces the Grant of Essential U.S. Patent for Its Stenoparib DRP® Companion Diagnostic	AQ
18/06	Allarity Therapeutics to Present Trial-in-Progress Poster on Phase 2 Stenoparib Trial at ESMO Gynaecological Cancers Congress 2026	AQ
15/05	Allarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple Cancers	AQ
08/05	Allarity Therapeutics CEO to Present at Precision Medicine Forum Europe 2026 in Stockholm	AQ
05/05	Allarity Therapeutics Advances Stenoparib Toward Pivotal Development with Phase 3 Manufacturing Campaign	AQ
27/04	Allarity Therapeutics Announces that the Stenoparib DRP® Test Has Received a Notice of Allowance from the US Patent and Trademark Office	AQ
21/04	Allarity Therapeutics Presents Two AACR 2026 Posters Highlighting Stenoparib’s Potential in Colorectal Cancer as well as New Predictive Data Linking DRP® and Overall Survival in Ovarian Cancer	AQ
31/03	Allarity Therapeutics Reports Full Year 2025 Financial Results and Corporate Progress	AQ
06/03	Allarity Therapeutics Closes $20 Million Financing to Accelerate the Advance of Stenoparib Toward FDA Approval and Commercialization	AQ
18/02	Allarity Therapeutics Doses First Patients in VA-Funded Phase 2 Trial Focused on Small Cell Lung Cancer with High Unmet Need	AQ
03/02	Allarity Therapeutics announces that its collaborative Phase 2 trial with the United States Veteran’s Administration Combining Stenoparib with Temozolomide in Relapsed Small Cell Lung Cancer is Now Open for Enrollment	AQ
31/12	Allarity Therapeutics Issues 2025 End of Year CEO Letter to Shareholders	AQ
14/11	Allarity Therapeutics Provides Third Quarter 2025 Financial Results and Provides Business Updates	AQ
30/09/25	CHOSA announces positive results from a clinical study in collaboration with ETOP/EORTC on platinum predictor in lung cancer	AQ
22/09/25	Allarity Therapeutics Presents New Phase 2 Clinical Data for Stenoparib/2X-121 Showing Landmark Median Overall Survival Has Now Surpassed 25 Months	AQ
17/09/25	Allarity Therapeutics CEO to Present at Biomarkers & Precision Medicine 2025	AQ
26/08/25	Allarity Therapeutics Granted FDA Fast Track Designation for Stenoparib for the Treatment of Advanced Ovarian Cancer	AQ
15/08/25	Allarity Therapeutics Provides Second Quarter 2025 Update, Highlighting Clinical Progress, IP Expansion, and New Partnerships	AQ
24/07/25	Allarity Therapeutics : Corporate Presentation 2025 Q2	PU
15/07/25	Allarity Therapeutics Announces New Licensing and Laboratory Services Agreement to Expand DRP® Platform Utilization	AQ
07/07/25	Allarity Therapeutics Announces Appointment of Jeff Ervin as Chief Financial Officer	AQ
30/06/25	Allarity Therapeutics Receives Australian Patent Acceptance Notice for Stenoparib DRP® Companion Diagnostic	AQ
27/06/25	Allarity Therapeutics Announces Dosing of Second Patient in New Phase 2 Trial of Stenoparib in Advanced Ovarian Cancer	AQ
11/06/25	Allarity Therapeutics Announces Changes to Board of Directors	AQ